期刊
DIABETES CARE
卷 35, 期 9, 页码 1864-1867出版社
AMER DIABETES ASSOC
DOI: 10.2337/dc11-2301
关键词
-
资金
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health
- NIDDK
- Indian Health Service
- Office of Research on Minority Health
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Office of Research on Women's Health
- Centers for Disease Control and Prevention
- American Diabetes Association
- T.I.P. McKesson BioServices Corp.
- Matthews Media Group, Inc.
- Henry M. Jackson Foundation
- National Institute on Aging
- [R01-DK-072041]
OBJECTIVE-The C allele at the rs11212617 polymorphism in the ataxia-telangiectasia-mutated (ATM) gene has been associated with greater clinical response to metformin in people with type 2 diabetes. We tested whether this variant modified the effect of metformin in the Diabetes Prevention Program (DPP), in which metformin reduced diabetes incidence by 31% in volunteers with impaired glucose tolerance. RESEARCH DESIGN AND METHODS-We genotyped rs11212617 in 2,994 DPP participants and analyzed its effects on diabetes incidence and related traits. RESULTS-Contrary to expectations, C carriers enjoyed no preventive advantage on metformin ; their hazard ratio, compared with A carriers, was 1.17 ([95% CI 0.96-1.42], P = 0.13) under metformin. There were no significant differences by genotype in metformin's effects on insulin sensitivity, fasting glucose, glycated hemoglobin, or disposition index. CONCLUSIONS-The reported association of rs11212617 with metformin response was not confirmed for diabetes prevention or for effects on relevant physiologic parameters in the DPP.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据